RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal

Key Takeaways Rapport shares surged after RAP-219 met goals in a phase IIa study for focal onset seizures.Treatment with the candidate cut seizure frequency, with 24% of patients achieving seizure freedom.Plans include FDA talks in 2025 and pivotal epilepsy studies starting in 2026.Shares of Rapport Therapeutics (RAPP) surged 61.6% in a week after the company reported positive top-line data from a mid-stage study of its lead candidate, RAP-219, in patients with drug-resistant focal onset seizures (FOS), a t ...